Genomtec (GMT) Investor Update summary

Management and organizational updates

• International team of 20 experts operates from Wrocław and Kent, UK, led by co-founder Miron Tokarsky, with deep expertise in molecular biology, finance, and photonics.

• Recent organizational restructuring aligns with the M&A process, creating dedicated subsidiaries for Genomtec ID, Onco SNAAT, and food safety projects to accelerate transactions and increase value.

Technology and product development

• Genomtec specializes in advanced genetic diagnostics, focusing on point-of-care solutions using proprietary SNAAT and LAMP isothermal amplification technologies.

• LAMP technology offers rapid, highly specific DNA/RNA detection at femtogram levels, with results in under 30 minutes and high resistance to sample inhibitors.

• Genomtec ID platform enables multiplexed, mobile, and low-cost diagnostics, with ongoing improvements in heating system stability and test speed.

M&A process and operational status

• M&A process ongoing since July 2023, with dozens of meetings, NDAs signed, and data exchanged with interested parties in five key areas.

• Technology validation includes environmental stability, cost reduction, and diagnostic acceleration, with confirmed heating system stability and reduced amplification times.

• Achieved over 70% reduction in production costs for cards and reagents, and up to 80% reduction in reagent costs through process optimization.